Single-cell level characterization of B cell depletion and repopulation following rituximab in systemic lupus erythematosus
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Objective
Rituximab, a CD20 + B cell depletion therapy, is frequently used in the treatment of systemic lupus erythematosus (SLE). However, variability in patient response highlights the need for a deeper understanding of the underlying immune cell dynamics of B cell depletion and repopulation.
Methods
In this study, we conducted longitudinal single-cell profiling of nine SLE patients treated with rituximab from pretreatment to up to 15 months post-treatment. These were compared to eight healthy controls. We profiled 169,513 immune cells via single-cell RNA, surface protein, B cell receptor (BCR), and T cell receptor (TCR) sequencing and sequenced bulk BCR repertoires in parallel.
Results
Significant depletion of naïve, memory, and age-associated B cells (ABCs) was observed early post-treatment, followed by later repopulation of mainly transitional B cells. BCR repertoire analysis revealed reduced diversity and persistent clones in antigen-experienced cells at early post-treatment, but these effects were not long-lasting. Notably, repopulated naïve B cells in rituximab responders exhibited reduced NF-κB pathway activation, aligning with lower BAFF-R surface protein levels. In non-B cells, we identified 27 differentially expressed genes across 7 immune cell subtypes post-rituximab, with regulatory CD4 T cells and double negative (DN) T cells showing the most transcriptional changes. Responders specifically had increased expression of genes related to cytotoxicity, MHC class II antigen presentation, and T cell activation in CD4 T central memory (TCM) and DN T cells.
Conclusion
Our longitudinal profiling provides single-cell resolution of the shifts in immune cell dynamics following B cell depletion.
